The present disclosure provides a system for the expression of target protein in conjunction with enhancer protein. The enhancer protein may be a viral protein that blocks nucleocytoplasmic transport. Also provided are polynucleotides, vectors, and cells comprising target protein and enhancer protein nucleic acid sequences.

The present disclosure provides a system for the expression of target protein in conjunction with enhancer protein. The enhancer protein may be a viral protein that blocks nucleocytoplasmic transport. Also provided are polynucleotides, vectors, and cells comprising target protein and enhancer protein nucleic acid sequences.

The invention relates to a messenger ribonucleic acid (mRNA) molecule lacking a cap molecule, for which the cost of in vitro transcription synthesis is greatly reduced, comprising, from 5 to 3, at least one copy of a GUCAGRYC(N.sub.7-19)GCCA(N.sub.12-19)UGCNRYCUG consensus sequence which is resistant to the Xrn1 exoribonuclease, a copy of an internal ribosome entry site (IRES) RNA sequence, and an open reading frame.

The present disclosure provides methods and compositions for the improved expression of target proteins via the co-expression of an enhancer protein in a subject. Provided herein are methods for expressing a target protein in a subject comprising administering a vector system of one or more polynucleotides encoding a target protein and an enhancer protein, wherein the polynucleotides are operatively linked, and wherein the enhancer protein is an inhibitor of nucleocytoplasmic transport (NCT) and/or the enhancer protein is selected from the group consisting of a picornavirus leader (L) protein, a picornavirus 2A protease, a rhinovirus 3C protease, a herpes simplex virus (HSV) ICP27 protein, and a rhabdovirus matrix (M) protein.

This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.

The disclosure provides recombinant viral vectors and attenuated viruses and viral vaccines comprising a virus lacking a functional viral RNA suppressor of host RNAi.

This document relates to methods and materials involved in treating and/or preventing and/or reducing the severity of a viral infection present in a mammal. For example, methods and materials for reducing the severity of a viral infection present in a mammal (e.g., a human) are provided.